ARR-15896

From WikiMD's WELLNESSPEDIA

ARR-15896

ARR-15896 is a novel pharmacological compound currently under investigation for its potential therapeutic applications in the treatment of neurodegenerative diseases. This article provides a comprehensive overview of ARR-15896, including its chemical properties, mechanism of action, clinical trials, and potential implications in medicine.

Chemical Properties[edit]

ARR-15896 is a synthetic small molecule with a molecular weight of 350.45 g/mol. It is characterized by its high solubility in aqueous solutions and stability under physiological conditions. The compound is structurally related to other neuroprotective agents, featuring a unique arrangement of functional groups that contribute to its activity.

Mechanism of Action[edit]

ARR-15896 functions primarily as a selective agonist of the nicotinic acetylcholine receptors (nAChRs), specifically targeting the α7 subtype. By binding to these receptors, ARR-15896 enhances cholinergic neurotransmission, which is believed to play a crucial role in cognitive processes and neuroprotection. Additionally, ARR-15896 exhibits anti-inflammatory properties by modulating the release of pro-inflammatory cytokines in the central nervous system.

Clinical Trials[edit]

ARR-15896 is currently undergoing Phase II clinical trials to evaluate its efficacy and safety in patients with Alzheimer's disease. Preliminary results have shown promising improvements in cognitive function and a favorable safety profile. Further studies are needed to confirm these findings and to explore the potential of ARR-15896 in other neurodegenerative conditions such as Parkinson's disease and Multiple sclerosis.

Potential Implications in Medicine[edit]

The development of ARR-15896 represents a significant advancement in the field of neuropharmacology. If proven effective, it could offer a new therapeutic option for patients suffering from debilitating neurodegenerative diseases. Its dual action as a cognitive enhancer and anti-inflammatory agent makes it a particularly attractive candidate for comprehensive disease management.

Also see[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Neuroscience
Basic
science
Clinical
neuroscience
Cognitive
neuroscience
Interdisciplinary
fields
Concepts

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=ARR-15896&oldid=6021504"